Dupilumab Emerging Drug Insight and Market Forecast - 2032

This “Dupilumab Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about dupilumab for bullous pemphigoid in the seven major markets. A detailed picture of the dupilumab for bullous pemphigoid in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the dupilumab for bullous pemphigoid. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the dupilumab market forecast analysis for bullous pemphigoid in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in bullous pemphigoid.

Drug Summary

Dupilumab (Dupixent) is a monoclonal antibody targeting the α chain of the interleukin (IL)-4 receptor. It inhibits the biological effects of the cytokines IL-4 and IL-13, which are key drivers in the TH2 response (Sastre, 2018).

Dupilumab is approved in the US to treat patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies; for use with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid-dependent asthma in patients aged 12 years and older whose asthma is not controlled with their current asthma medicines; and for use with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. In adolescents 12 years of age or older, it is recommended that dupilumab be administered by or under an adult's supervision.

In addition to the currently approved indications, Regeneron and Sanofi are also investigating dupilumab in a broad range of clinical development programs for diseases driven by allergic and other Type 2 inflammation, including peanut allergy, grass allergy, AD in pediatric patients, asthma in pediatric patients, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), bullous pemphigoid (BP), prurigo nodularis, chronic spontaneous urticaria, and allergic bronchopulmonary aspergillosis.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the dupilumab description, mechanism of action, dosage and administration, research and development activities in bullous pemphigoid.
• Elaborated details on dupilumab regulatory milestones and other development activities have been provided in this report.
• The report also highlights the dupilumab research and development activities in bullous pemphigoid across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around dupilumab.
• The report contains forecasted sales of dupilumab for bullous pemphigoid till 2032.
• Comprehensive coverage of the late-stage emerging therapies for bullous pemphigoid.
• The report also features the SWOT analysis with analyst views for dupilumab in bullous pemphigoid.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Dupilumab Analytical Perspective

In-depth Dupilumab Market Assessment

This report provides a detailed market assessment of dupilumab for bullous pemphigoid in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Dupilumab Clinical Assessment

The report provides the clinical trials information of dupilumab for bullous pemphigoid covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for bullous pemphigoid is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence dupilumab dominance.
• Other emerging products for bullous pemphigoid are expected to give tough market competition to dupilumab and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of dupilumab in bullous pemphigoid.
• This in-depth analysis of the forecasted sales data of dupilumab from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the dupilumab in bullous pemphigoid.

Key Questions

• What is the product type, route of administration and mechanism of action of dupilumab?
• What is the clinical trial status of the study related to dupilumab in bullous pemphigoid and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the dupilumab development?
• What are the key designations that have been granted to dupilumab for bullous pemphigoid?
• What is the forecasted market scenario of dupilumab for bullous pemphigoid?
• What are the forecasted sales of dupilumab in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to dupilumab for bullous pemphigoid?
• Which are the late-stage emerging therapies under development for the treatment of bullous pemphigoid?

This product will be delivered within 2 business days.